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Genome-wide homozygosity 
signature and risk of Hodgkin 
lymphoma
Amit Sud1, Rosie Cooke1, Anthony J. Swerdlow1,2 & Richard S. Houlston1
Recent studies have reported that regions of homozygosity (ROH) in the genome are detectable 
in outbred populations and can be associated with an increased risk of malignancy. To examine 
whether homozygosity is associated with an increased risk of developing Hodgkin lymphoma 
(HL) we analysed 589 HL cases and 5,199 controls genotyped for 484,072 tag single nucleotide 
polymorphisms (SNPs). Across the genome the cumulative distribution of ROH was not significantly 
different between cases and controls. Seven ROH at 4q22.3, 4q32.2, 7p12.3–14.1, 7p22.2, 10p11.22–
23, 19q13.12-2 and 19p13.2 were associated with HL risk at P < 0.01. Intriguingly 4q22.3 harbours 
an ROH to which the nuclear factor NF-kappa-B p105 subunit (NFKB1) maps (P = 0.002). The ROH at 
19q13.12-2 has previously been implicated in B-cell precursor acute lymphoblastic leukaemia. Aside 
from these observations which require validation, it is unlikely that levels of measured homozygosity 
caused by autozygosity, uniparental isodisomy or hemizygosity play a major role in defining HL risk 
in predominantly outbred populations.
Hodgkin lymphoma (HL) is a B-cell malignancy which affects around 3 per 100,000 of the population 
each year in most western countries1. The cancer is conventionally classified based on its histopath-
ogy into classical HL (cHL), which accounts for 95% of cases, and nodular lymphocyte predominant 
HL (NLPHL). The presence of Epstein-Barr virus (EBV) latent membrane protein and/or EBV-encoded 
small RNAs (EBERs) in Hodgkin Reed-Sternberg cells (HRS) defines EBV-positive disease2.
Evidence for inherited genetic predisposition to HL is provided by the three to nine-fold increased 
risk of HL in first-degree relatives of HL patients3. To date, no high penetrance susceptibility loci have 
been identified for HL and most of the inherited risk is likely to be the consequence of the co-inheritance 
of multiple low-risk variants. Genome-wide association studies (GWAS) of HL have identified several 
common (minor allele frequency [MAF] > 5%) single nucleotide polymorphisms (SNPs), at 2p16.1 
(REL), 3p24.1 (EOMES), 6q23.3 (HBSL1L, MYB), 8q24.21 (PVT1), 10p14 (GATA3), 19p13.3 (TCF3), as 
well as multiple associations within 6p21 (HLA region)4–9. While SNPs (excluding some located in the 
HLA region) individually confer small effects (odds ratio [OR] < 1.6) on HL risk they have given novel 
insights into HL biology implicating perturbation of the Rel/NF-κ B pathways in disease aetiology.
The majority of cancer predisposition SNPs that have been identified to date through GWAS act in a 
co-dominant fashion and studies have found no good evidence for recessively acting alleles10. Although 
this may be reflective of the biology, it may also be a consequence of GWAS having suboptimal ability 
to detect recessively acting disease-alleles. Clues that tumour susceptibility may have a recessive basis 
come from reports of an increased incidence associated with consanguinity and in populations char-
acterised by a high degree of inbreeding11–16. Further evidence for the role of homozygosity in cancer 
predisposition is provided by experimental animal inbreeding (e.g. backcrossing mice) increasing tumour 
incidence17. Specific situations of homozygosity have also been directly associated with cancer such as 
uniparental disomy through altered imprinting18.
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Common regions of homozygosity (ROH), the result of autozygosity (i.e. the occurrence of two alleles 
at the same locus originating from a common ancestor by way of non-random mating), have been shown 
to occur at high frequency in outbred populations as a result of selection19. Searching for ROH on a 
genome-wide basis therefore provides a strategy for exposing recessively acting disease genes. Recently 
Yang et al. studied patients with rheumatoid arthritis (RA) of Northern/Western European ancestry by 
whole-genome loss of heterozygosity analysis using Affymetrix SNP arrays20. A significant increase in 
the frequency of homozygosity was shown in cases compared with controls in the HLA region, a locus 
known to be associated with RA risk. Simón-Sánchez et al. showed that cases of early onset Parkinson’s 
disease  harboured significantly more homozygous regions than healthy individuals21. Findings from 
these studies support the hypothesis that there exist multiple, recessive, disease-predisposing loci, which 
are not readily detected using a conventional GWAS approach based on analysis of individual SNPs. A 
possible explanation for this is that relative risks per locus are too low and/or that the disease-associated 
variants are not in strong linkage disequilibrium (LD) with tagSNPs, perhaps because of low allele 
frequencies.
While GWAS have limited ability to identify recessive disease alleles through single SNP analyses, 
these datasets can potentially be exploited to search for recessively acting disease loci through whole 
genome homozygosity analysis (WGHA). Hence to examine whether homozygosity is associated with 
an increased risk of developing HL and to search for novel recessively-acting disease loci, we conducted 
a WGHA of 589 HL cases and 5,199 controls genotyped for 484,072 tagging SNPs4.
Study Design
Patients and DNA samples. We analysed the constitutional DNA of 622 patients with HL ascer-
tained from the UK. Details of the study are provided in previously published material4.
Control series. We used data from two publicly accessible data series for population SNP gen-
otype frequencies: individuals from the UK Welcome Trust Case-Control Consortium 2 (WTCCC2) 
study of 2,930 individuals from the 1958 British Birth Cohort (58C; also known as the National Child 
Development Study)22 and 2,737 individuals from the UK Blood Service collections (UKBS), all of which 
were combined to provide genotype data from 5,667 controls.
Ethics. Collection of blood samples and clinico-pathological information from subjects was under-
taken with informed consent and relevant ethical review board approval (the Royal Marsden Hospital 
NHS Trust and Multicentre Research Ethics Committee) in accordance with the tenets of the Declaration 
of Helsinki.
Genotyping. As previously described4, DNA from the cases was extracted and quantified from 
EDTA-venous blood samples using conventional methodologies and a genome-wide scan of tagging 
SNPs conducted using Illumina Infinium 660w-Quad Bead Chips according to the manufacturer’s pro-
tocols (Illumina, San Diego, USA). The control series had already been genotyped using the Illumina 
Human1.2M-Duo Custom_v1 Array BeadChips. We restricted our analysis to the autosomal SNPs. We 
considered that a DNA sample had failed if it did not generate a genotype for > 95% of loci. Similarly, 
a SNP was considered a failure if < 95% of DNA samples generated a genotype at the locus. To ensure 
quality of genotyping, a series of duplicate samples were genotyped on the same arrays, with concordance 
rates of > 99.9%. The overall genotyping call rate was 99.92%.
Quality control. To identify samples showing relatedness, identity by state values (IBS) were cal-
culated for pairs of individuals. For any pair with > 80% identical SNP genotypes, we removed the 
sample with the lower call rate from the analysis. We excluded SNPs on the basis of deviation from 
Hardy-Weinberg Equilibrium (HWE) using a threshold of P < 1 × 10−5 in either the cases or controls, 
which resulted in only 139 SNPs being removed from the analysis. We also removed SNPs with MAF 
< 0.05. To identify and exclude individuals with non-Western European ancestry, case and control data 
were merged with data obtained from individuals of different ethnicities from the International HapMap 
Project, from genome-wide IBS distances for markers shared between HapMap and our SNP panel, and 
from dissimilarity measures used to perform principal component analysis. After imposing these strin-
gent quality control measures, 484,072 SNP genotypes were available on 589 HL cases and 5,199 controls 
which formed the basis of our analysis.
Statistical and bioinformatics analysis. We detected ROH using PLINK v1.9023, which moves a 
sliding window of SNPs across the entire genome. To allow for genotyping error or other sources of 
artificial heterozygosity (such as paralogous sequences) within a stretch of truly homozygous SNPs, 2% 
heterozygous SNPs were allowed in each window. This was done to prevent underestimation of the 
number and size of ROH. We left the remaining options set to the default values (including allowing 5 
missing calls per window), except that we varied the parameter homozyg-snp according to our heuristic 
preferences for defining the ROH as detailed below. Subsequent statistical analyses were performed using 
packages available in R (version 3.1.2) and specifically written Perl code. Comparison of the distribution 
of categorical variables was performed using the χ2 test. To compare the difference in average number 
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of ROH between cases and controls we used the Student t-test. Naïve adjustment for multiple testing was 
based on the Bonferroni correction. In addition to conducting a PLINK-based analysis of ROH we also 
subsequently analysed our data using SNP & Variation Suite 8 software (Golden Helix, Bozeman, MT, 
USA) which is based on implementation of a fixed window.
We used three metrics to investigate the selection pressure on each ROH. Integrated Haplotype Score 
(iHS) is based on LD surrounding a positively selected allele compared to background, providing evi-
dence of recent positive selection at a locus24. An iHS score > 2.0 reflects that haplotypes on the ancestral 
background are longer compared to the derived allelic background. Episodes of selection tend to skew 
SNP frequencies in different directions and Tajima’s D is based on the frequencies of SNPs segregating in 
the region of interest25. Fixation index (Fst) measures the degree of population differentiation at a locus, 
taking values from 0 to 1.026. iHS, D and Fst metrics were obtained from dbPSHP27.
Identification of ROH. In order to focus on commonly occurring ROH and to empower our analysis 
to identify meaningful associations, only ROH in which 10 or more individuals shared the same ROH 
were retained for analysis. The initial search for ROH was performed using PLINK23 with a specified 
length of 84 consecutive SNPs (homozyg-snp parameter). This ROH length was chosen to be more than 
an order of magnitude larger than the mean haploblock size in the human genome without being so 
large as to be very rare. The likelihood of observing 84 consecutive chance events can be calculated as 
follows19. Mean heterozygosity in the controls was calculated to be 34%. Thus, given 484,072 SNPs and 
5,788 individuals, a minimum length of 60 would be required to produce < 5% randomly generated ROH 
across all subjects ([1 − 0.34]60 × 484,072 × 5788 = 0.043). A consequence of LD is that the SNP geno-
types are not always independent, thereby inflating the probability of chance occurrences of biologically 
meaningless ROH. Analysis based on PLINK’s pairwise LD SNP pruning function showed 363,152 sepa-
rable tag groups, representing a 25% reduction of information compared to the original number of SNPs. 
Thus ROH of length 84 were used to approximate the degrees of freedom of 60 independent SNP calls.
Once all ROH of at least 84 SNPs in length were identified, these were pruned to only those ROH that 
occurred in more than 10 individuals. To ensure that a minimum length and minimum number of SNPs 
in each ROH was maintained, each individual’s SNP data were recoded as one if the SNP was in an ROH 
for that individual and zero otherwise. Then, for each SNP, those SNPs with fewer than 10 individuals 
coded as one were recoded to zero before removing any ROH that due to this recoding were now less 
than the required number of SNPs in length. This process therefore resulted in a list of “common” ROH 
having a minimum of 75 consecutive ROH calls across 10 or more samples and with each ROH having 
the same start and end locations across all individuals where that ROH is observed.
Results
We have previously subjected cases and controls to rigorous quality control in terms of excluding sam-
ples and SNPs with poor call rates. Furthermore, we excluded SNPs showing significant departure from 
HWE. The results in Tables 1 and 2 were not substantively different when including the additional 139 
SNPs that failed the HWE threshold of P < 1 × 10−5. We evaluated datasets for ancestral differences by 
principal component analysis and removed all outliers. Figure 1 shows that the final sample series used 
were ancestrally comparable and hence could be pooled without introducing systematic bias.
ROH Chromosome Start, bp End, bp Length, bp
No. of 
SNPs
% of 
controls iHSmax
Tajima 
Dmax Fstmax
ROH83 3 74364811 115347556 40982745 4861 50 3.30 4.27 0.52
ROH212 8 41237437 58695807 17458370 1660 43 3.00 3.99 0.40
ROH159 6 53470082 88671201 35201119 4749 40 3.36 4.00 0.43
ROH272 11 44985936 60832282 15846346 1379 39 2.52 3.93 0.80
ROH60 2 133966177 142500134 8533957 1532 35 3.10 4.25 0.56
ROH153 6 24729115 33874440 9145325 2439 34 4.18 4.59 0.51
ROH215 8 74146766 96245252 22098486 3065 30 2.87 4.45 0.33
ROH103 4 27284946 37133279 9848333 1366 30 2.78 4.59 0.43
ROH196 7 106400535 130396888 23996353 3310 29 3.55 4.63 0.42
ROH126 5 39081475 53519724 14438249 1551 28 2.47 3.78 0.38
ROH188 7 47907214 70407537 22500323 2518 26 3.02 4.50 0.70
ROH137 5 125886071 132587049 6700978 882 25 2.78 4.10 0.31
Table 1.  List of ROH with frequency of >25% in the controls. Chromosomal coordinates derived from 
the National Center for Biotechnology Information (NCBI) build 36. *Represent maximal values for several 
metrics of positive selection, derived from dbpSHP27.
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Using PLINK a total of 398 common ROH were identified in samples (Supplementary Table 1), 
encompassing approximately 60% of the autosome as measured by total chromosomal length. Figure 2 
shows correlation between the frequency of individual ROH in the cases and the controls, while Fig. 3 
shows the similarity between the genome-wide plots of the location of each ROH among the genomes of 
HL cases and controls. We repeated our ROH analysis of cases and controls using SNP & Variation Suite 
Software. Our findings were not materially affected using this alternative approach; hence we confined 
our further analysis to PLINK-based methodology.
The 37 longest ROH exceeded 12 Mb in length each and included ROH encompassing the centro-
meric regions of chromosomes 1, 2, 3, 4, 5, 6, 7, 8, 11, 12, 16, and 20. The lengths of these ROH are 
partly a consequence of long regions for which there are no annotating SNPs. This is however unlikely 
to be the sole explanation, as in each case these centromeric regions were flanked by large homozy-
gous regions containing numerous SNPs. One of these centromeric regions (chromosome 8) has been 
ROH Chromosome Start, bp End, bp Length, bp
No. of 
SNPs
No. (%) 
of cases
No. (%) of 
controls Χ2 P
ROH118 4 164181835 165694435 1512600 280 7 (1.18) 16 (0.31) 10.47 0.0012
ROH111 4 96397988 109621884 13223896 1816 101 (17.15) 660 (12.70) 9.86 0.0017
ROH174 7 3362918 4133399 770481 196 4 (0.68) 6 (0.12) 9.81 0.0017
ROH378 19 36097328 39542089 3444761 355 28 (4.75) 442 (8.50) 9.53 0.0020
ROH375 19 9314135 12772090 3457955 412 12 (2.04) 43 (0.83) 8.39 0.0038
ROH187 7 43086042 46983232 3897190 648 11 (1.87) 38 (0.73) 8.29 0.0040
ROH251 10 30830837 33710224 2879387 483 25 (4.24) 126 (2.42) 7.15 0.0075
Table 2.  List of ROH associated with HL risk (P < 0.01).
Figure 1. Identification of individuals in the GWAS of non-European ancestry. The first two principal 
components of the analysis were plotted. HapMap CEU individuals are plotted in blue; CHB + JPT 
individuals are plotted in green; YRI individuals are plotted in red; GWAS cases are plotted in pink before 
(a) and after (c) removal, GWAS controls are plotted pink before (b) and after (d) removal.
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previously highlighted in several genome-wide studies of selective sweeps, thus providing validation of 
our methodology24,28–30. Twenty-five non-centromeric regions harbouring ROH greater than 12 Mb in 
length were identified in our study (Supplementary Table 1).
The ROH covering the largest genomic region (40 Mb) and the largest number of SNPs (2885) was 
found to be ROH83 spanning the centromere of chromosome 3, a region previously shown to be char-
acterised by a high frequency of ROH in the European population28.
There are twelve ROH that were very common (> 25% frequency) in the control series (Table  1). 
Five of these are included in the nine most common ROH found in Lencz et al.19 and harbour several 
gene categories identified in various studies that appear to be influenced by a high degree of selective 
Figure 2. Comparison between the frequencies of the 398 ROH identified, in HL cases and the controls. 
The seven ROH coloured black are those that are significantly associated with HL risk (P < 0.01) and the 
horizontal line shows ROH with frequency > 25% in controls.
Figure 3. Plots showing the location of the ROH identified in HL cases and controls. The location of the 
ROH in the genomes of the cases is shown in (A) and the controls (B).
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pressure24,28–30. Publicly available data from HapMap and the WTCCC do not indicate that these regions 
have excessive copy number variation or segmental duplication, nor do they have very low recombi-
nation rates31. However, the high iHS, D and Fst metrics for each region are compatible with positive 
selection in Caucasian populations (Table 1).
The total number of common ROH observed in each individual was calculated to permit genome-wide 
comparison between the case and control groups. Each individual ROH therefore was assigned a value 
between 0 and 398. Overall, patients with HL (mean = 17.7, SD = 4.6) and controls (mean = 17.8, 
SD = 4.0) showed no significant difference in the average number of ROH (t5788 = 0.2851, P = 0.76). To 
also examine whether there were differences in the distributions of ROH in the genomes of cases and 
controls we computed the cumulative distributions of both series (Fig.  4). This analysis also provides 
no support for a difference in autozygosity profiles between cases and controls on a genome-wide basis.
At an individual level seven ROH, none of which include an excessive number of copy number vari-
ants, differed significantly (P < 0.01) between cases and controls (Table 2). Adjusting for age and sex did 
not yield a significant difference in results. While these associations were not individually statistically 
significant after adjusting for multiple testing using the Bonferroni correction, imposing such adjustment 
is highly conservative and can lead to type 2 error. Six of these seven, marginally significant, ROH were 
more common in the controls than in the cases.
ROH111 was identified in 17.1% of cases (n = 101) compared with 12.7% of controls (n = 660) 
(P = 0.0017). Over 50 genes or predicted transcripts map to the region encompassed by this ROH includ-
ing the gene encoding NF-kappa-B p105 subunit (NFKB1; MIM 164011). Although speculative, it is 
intriguing to note that NF-κ B pathways are constitutively overactive in a variety of lymphomas including 
HL32,33. Mutations in NFKB1 have been identified in tumour samples from patients with HL34, and c-Rel 
encoded by REL (a known causative locus in HL) interacts with NF-kappa-B p105 subunit as a mediator 
of immune and inflammatory responses4,35. We explored the possibility of a relationship between NFKB1 
genotype and HL risk through single point analysis based on SNPs that map within 25 kb of the gene. 
The strongest association was provided by an imputed SNP located in an intron of NFKB1, rs4647965 
(OR = 1.9, Pcohrane−armitage = 0.0004, info = 0.79).
Discussion
Recent studies have provided evidence that signatures of autozygosity correlate to cancer incidence and 
that these regions showing identity by descent may be the locations of genes contributing to tumour 
heritability36,37 as well as other diseases20,21. These data have been interpreted as providing an explanation 
for the increased cancer rates reported in some inbred populations11,13,14.
Here we have used a high-density genomic scan to compare the structure of genetic variation in 
patients with HL with healthy controls. This same sample series has recently been used to identify six 
predisposition loci for HL4,8. By imposing stringent quality control we have ensured individuals in our 
study were from an apparently panmictic population (i.e. population where all individuals are potential 
partners) with no evidence of stratification. Our data provide further evidence that ROH, ranging in size 
from 6 to 40 Mb, are common in individuals from an outbred population38–41. As documented in Table 1, 
the common ROH we identified are representative of autozygosity due to distant consanguinity and not 
chromosomal abnormalities or common copy number variants. Moreover these homozygous regions are 
too common and small to be a consequence of recent consanguinity and are consistent with the possibil-
ity that they mark regions under selective pressure42. Based on our analysis there was no evidence for an 
association between homozygosity and HL risk on the basis of total ROH size per individual. While not 
formally statistically significant after adjustment for multiple testing, the associations between HL risk 
and ROH, as demonstrated by ROH111 (which harbours NF-κB1), and ROH375 (previously implicated 
Figure 4. Cumulative distributions of ROH in HL cases and controls. The graph is presented in such a 
way that each data point represents the cumulative fraction (y-axis) of the samples with the corresponding 
minimum cumulative run of homozygosity (x-axis).
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in susceptibility to childhood B-cell precursor acute lymphoblastic leukaemia [BCP-ALL])43, may reflect 
regions that warrant further investigation.
The assertion that increased autozygosity correlates with cancer incidence provides an attractive 
explanation for reported increased cancer risk in inbred populations. However, as recently articulated, 
several criticisms can be levelled at such an idea44. The observation of an increased cancer risk associ-
ated with consanguinity has often been based on studies of a small number of individuals in an isolated 
community or a single large family with a high level of inbreeding. Thus, the relevance of inbreeding to 
the population risk of cancer is unclear, as inbreeding and founder effects may be confounded. Sample 
sizes in the molecular studies36,37, which have sought to establish a relationship between ROH and can-
cer risk have generally been small and, crucially, case and control groups ethnically heterogeneous or 
unmatched. Here we have addressed these possible shortcomings in our study of HL by analysing a large 
set of cases and controls that have been genotyped for several hundred thousand SNPs and imposed a 
high level of quality control both in terms of genotyping and sample ancestry. In addition, WGHA in 
breast, prostate and colorectal cancer as well as childhood BCP-ALL have found limited evidence that 
measured homozygosity confers an increased risk of developing these cancers43–45.
In conclusion our findings make it unlikely that levels of measured common homozygosity, from 
autozygosity, uniparental isodisomy or hemizygosity, play a significant role in defining the risk of devel-
oping HL in a predominantly outbred population. Moreover it is unlikely that there exist large numbers 
of recessive alleles in most European populations, that predispose to HL and are unmasked by autozy-
gosity. This analysis does not however exclude the possibility that recessively acting disease alleles exist 
for HL.
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